SIDF：2022年沙特阿拉伯聚焦市场活性药物成分API（英文版）（20页）.pdf

1、Market in Focus:Active Pharmaceutical Ingredients(APIs)December 2022Contents2Market in Focus:Active Pharmaceutical Ingredients(APIs)Key HighlightsGlobal MarketsKingdom Market Major ChallengesSuccess Factors0311162020Disclaimer This Report,including data,information,methodologies,and opinions reflect

2、ed herein contained or is for general information pur-poses only.The material in this Report is obtained from SIDF per dating of the report.SIDF has taken reasonable care to ensure that,and to the best of our knowledge,material information contained herein is in accord-ance with the facts and contai

3、ns no omission likely to affect its understanding.SIDF makes every effort but cannot and does not represent or warranty of any kind,whether express or implied,as to,the accuracy,reliability,or suitability of the information,products,services,or related graphics in this Report for any purpose.SIDF as

4、sumes no liability or responsibility of any kind for any errors or omissions in the content of this Report and further disclaims any liability of any nature for any loss howsoever caused in connection with using this Report.The materials and information in this Report are subject to change at any ti

5、me without prior notice.3Market in Focus:Active Pharmaceutical Ingredients(APIs)Key Highlights The global API market is SR 786 billion per annum during 2021 and is expected to grow at a CAGR of 6%during the next five years.Faster growth is projected for the biologic APIs segment,given its strong eff

6、icacy and high profitability,at a CAGR of 7.8%.Global top three active pharmaceutical ingredients(APIs),adali-mumab,immunoglobulin&ustekinumab,contribute to 30%of the value.Adalimumab&immunoglobulin are growing at a CAGR of 10%,while ustekinumab is growing at 39%.China and India have an advantage of